(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more (MM) Charts. Click Here for more (MM) Charts.](/p.php?pid=staticchart&s=N%5EIDIX&p=8&t=15)
Idenix Pharmaceuticals Selected to Join the NASDAQ Biotechnology
Index
CAMBRIDGE, Mass., May 16 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals,
Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery,
development and commercialization of drugs for the treatment of human viral and
other infectious diseases, today announced that it has been selected to join
the NASDAQ Biotechnology Index, effective with the market open on May 23, 2005.
Launched in 1993, the NASDAQ Biotechnology Index includes pharmaceutical and
biotechnology companies as classified by the FTSE(TM) Global Classification
System. The Index is ranked on a semi-annual basis in May and November and
serves as the basis for the iShares NASDAQ Biotechnology Index Fund(SM)
(AMEX:IBB). All securities in the NASDAQ Biotechnology Index are listed on the
NASDAQ National Market and meet minimum requirements including market value,
average daily share volume, and seasoning as a public company among other
criteria. For more information about the NASDAQ Biotechnology Index, including
eligibility criteria, visit http://www.nasdaq.com/.
About Idenix
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) is a biopharmaceutical company
engaged in the discovery, development and commercialization of drugs for the
treatment of human viral and other infectious diseases. Idenix's current focus
is on the treatment of infections caused by hepatitis B virus, hepatitis C
virus and human immunodeficiency virus (HIV). Idenix's headquarters are located
in Cambridge, Massachusetts. The company also has drug discovery and
development operations in Montpellier, France and drug discovery operations in
Cagliari, Italy. For further information about Idenix, please refer to
http://www.idenix.com/.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995. Statements in this press
release other than those that are historical in nature are "forward-looking
statements." Forward looking statements, which include statements with respect
to the potential therapeutic benefits and successful development of the
company's product candidates and the company's drug discovery and research,
regulatory approval processes and commercialization activities, are subject to
numerous factors, risks and uncertainties that may cause actual events or
results to differ materially from the company's current expectations. These
risks and uncertainties relate to the results of clinical trials and other
studies with respect to the product candidates that the company has under
development; the timing and success of submission, acceptance and approval of
regulatory filings; the company's dependence on its collaboration with Novartis
Pharma AG; the company's ability to obtain additional funding required to
conduct its research, development and commercialization activities; the ability
of the company to attract and retain qualified personnel and the company's
ability to obtain, maintain and enforce patent and other intellectual property
protection for its product candidates and its discoveries. These and other
risks are described in greater detail under the caption "Factors That May
Affect Future Results" in Item 7 of the company's quarterly report on Form 10-Q
for the quarter ended March 31, 2005 and filed with the Securities and Exchange
Commission and other filings that the company makes with the Securities and
Exchange Commission.
All forward-looking statements reflect the company's expectations only as of
the date of this release and should not be relied upon as reflecting the
company's views, expectations or beliefs at any date subsequent to the date of
this release. Idenix anticipates that subsequent events and developments may
cause these views, expectations and beliefs to change. However, while Idenix
may elect to update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so.
Contact:
Idenix Pharmaceuticals, Inc.
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838
DATASOURCE: Idenix Pharmaceuticals, Inc.
CONTACT: Teri Dahlman, Media, +1-617-995-9905, or Amy Sullivan,
Investors, +1-617-995-9838, both of Idenix Pharmaceuticals, Inc.
Web site: http://www.idenix.com/